Jaguar Health Q1 net revenue drops 25% YoY to $2.0M; OnTarget top line due Oct 2023

Jaguar Health, Inc.

2023-Q1 EPS reported -$2.39

Net revenue $2.0M, down 25% YoY from $2.6M and 40% QoQ from $3.3M.
Net loss to common stockholders improved to $12.2M from $18.0M YoY; EPS –$2.39 vs –$23.10.
PIPE closed raising ~$1.86M; no equity issuance before Oct 22, 2023 under agreement.
Phase 3 OnTarget trial enrollment completed; top line results expected October 2023.
IND submission for crofelemer in MVID planned Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jaguar Health, Inc. reported first quarter 2023 results: revenue $2.00 million.

Period: first quarter 2023
Revenue: $2.00 million
Result: reported results

Exact text from the filing

The combined net revenue for Mytesi ® and the Company’s other prescription product, Canalevia ® -CA1, which became commercially available in April 2022, was approximately $2.00 million in the first quarter of 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-060256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.